Last Updated : April 26, 2022
This Horizon Scan summarizes available information regarding tirzepatide for the treatment of high blood glucose associated with Type 2 diabetes. Tirzepatide is a first-in-class dual glucagon-like polypeptide-1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist currently under development. Tirzepatide demonstrates efficacy in reducing mean glycated hemoglobin (A1C) compared to placebo, semaglutide, insulin degludec, and insulin glargine. Studies investigating the possible effect of tirzepatide on cardiovascular outcomes are currently ongoing.